Amends TCA Title 33; Title 53; Title 63 and Title 68.

ON MARCH 31, 2022, THE SENATE ADOPTED AMENDMENT #1 AND PASSED SENATE BILL 2240, AS AMENDED. AMENDMENT #1 rewrites this bill to prohibit a healthcare provider who is authorized to prescribe buprenorphine under federal law from prescribing via telehealth a buprenorphine product, as approved by the federal food and drug administration for use in recovery or medication-assisted treatment, unless: (1) The healthcare provider is employed by or contracted with: (A) A licensed nonresidential office-based opiate treatment facility or licensed nonresidential opioid treatment program; (B) A community mental health center; (C) A federally qualified health center; (D) A licensed hospital; or (E) The bureau of TennCare's comprehensive enhanced buprenorphine treatment network; and (2) The delivery of telehealth is being provided on behalf of the entity that employs or contracts with the provider.